Trust Signals
Key Takeaways
- Bachem, PolyPeptide Group, and Lonza Peptide Synthesis hold the largest dedicated GMP peptide API capacity globally as of 2025, each capable of multi-hundred-kilogram annual output.
- Fmoc SPPS is the dominant synthesis platform at commercial CDMOs; TFA counterion residuals in the final API are a regulatory concern for injectables that many generic vendor pages do not address.
- A GMP-capable CDMO should be able to produce a Type II Drug Master File (DMF) or EU Active Substance Master File (ASMF) as a baseline deliverable for IND or CTA support.
- Process development timelines for a novel peptide API typically run 6 to 18 months before a first GMP batch, depending on sequence complexity and whether new analytical methods are required.
- Analytical completeness matters as much as synthesis capability: a COA without mass spectrometry confirmation, counterion quantification, and residual solvent data is insufficient for regulatory submission.
Direct Answer: Which CDMOs Are Best for Peptide Therapeutics Process Development?
The best CDMOs for peptide therapeutics process development are Bachem, PolyPeptide Group, Lonza Peptide Synthesis, Almac Sciences, and CPC Scientific. Each owns dedicated GMP SPPS infrastructure, in-house MS-grade analytical suites, and a track record of regulatory filings. The right choice depends on your peptide's complexity, your target scale, and the regulatory market you are filing in.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What should I look for in a peptide CDMO?
- Which CDMOs rank highest and why?
- Evidence ledger: what is the quality of available data?
- How does SPPS scale-up actually work, with real numbers?
- What most CDMO comparison pages get wrong
- Why TFA counterion matters: the chemistry behind the rule
- Head-to-head comparison table
- Can a CDMO handle cyclic, stapled, or lipidated peptides?
- How to read a peptide CDMO's COA and DMF
- Red flags and green flags when qualifying a CDMO
- FAQ
What Should I Look for in a Peptide CDMO?
Peptide API manufacturing is a specialized discipline. The following capabilities are non-negotiable for a sponsor entering IND-enabling or GMP manufacturing:
- On-site SPPS reactors at target scale. A CDMO that outsources the synthesis step to a sub-contractor cannot provide a clean chain-of-custody for a regulatory filing and introduces undisclosed quality variables.
- Preparative RP-HPLC purification in-house. Peptides are typically purified by reversed-phase preparative HPLC. Vendors without their own large-column HPLC hardware will bottleneck at purity specification and cannot troubleshoot purification process development efficiently.
- Analytical suite aligned with ICH Q6B. This means RP-HPLC purity, ESI-MS or MALDI identity confirmation, amino acid analysis, Karl Fischer water content, residual solvents (ICH Q3C), counterion quantification, and endotoxin testing for parenteral-grade material.
- Regulatory filing track record. Ask for the number of Type II DMFs or ASMFs active or previously filed, and whether the facility has passed an FDA or EMA GMP inspection within the last three years. Inspection outcomes are publicly accessible via the FDA's Establishment Inspection Report database.
- Process development capacity, not just manufacturing capacity. Sponsors often engage CDMOs too late. A CDMO with a dedicated process chemistry group can optimize coupling conditions, resin loading, and purification gradient during development, directly reducing cost-of-goods at commercial scale.
Which CDMOs Rank Highest and Why?
1. Bachem (Switzerland, USA)
Bachem is the highest-volume dedicated peptide manufacturer globally. The company produces both research-grade and GMP peptide APIs, operates SPPS and solution-phase synthesis platforms, and has an in-house resin and reagent manufacturing capability that reduces supply chain risk. Their regulatory track record includes support for multiple FDA-approved peptide drugs. They are the strongest choice for complex sequences, large commercial scale, or when a comprehensive DMF package is a near-term requirement. Their process development group publishes in peer-reviewed synthesis journals, which is an observable proxy for technical depth.
2. PolyPeptide Group (Sweden, Denmark, France, USA, India)
PolyPeptide Group operates multiple GMP facilities across continents, making it the most geographically diversified peptide CDMO. This matters for sponsors who need EU GMP and FDA GMP from the same supply chain, or who need regulatory redundancy. The multi-site structure also enables tech transfer from development-scale to commercial-scale within the same quality system. PolyPeptide has publicly disclosed support for more than 30 approved peptide APIs across global markets.
3. Lonza Peptide Synthesis (Switzerland, USA)
Lonza's peptide synthesis division (operating under Lonza Pharma and Biotech) combines large-scale SPPS capability with Lonza's broader drug substance and drug product infrastructure. This integrated model is valuable for sponsors who need peptide API synthesis and downstream formulation (including injectable fill-finish) under the same quality agreement. Particularly strong for GLP-1 class analogs and lipidated peptides given their fatty acid conjugation capabilities.
4. Almac Sciences (UK, USA)
Almac is a strong choice for Phase I and Phase II clinical material. Their process development group has documented capability with non-natural amino acids, stapled peptides, and peptide-drug conjugates. Scale tops out well below Bachem or PolyPeptide for commercial supply, but for early-phase sponsors this is not a limitation. Their integrated analytical services group is a genuine differentiator for sponsors who need rapid method development.
5. CPC Scientific (USA, China)
CPC Scientific offers competitive pricing and fast turnaround for research and early clinical-phase peptides. GMP capability is present but should be independently verified for the specific product type before engagement. Best suited for sponsors who need rapid process scouting with a path to GMP rather than immediate large-scale GMP production.
Notable Mentions
Pepgen (acquired capabilities), Pepscan, Creative Peptides, and Genscript Biotech serve research and early development needs but have more limited GMP regulatory track records. For complex antibody-peptide or peptide-oligonucleotide conjugates, CordenPharma and WuXi STA have demonstrated specific conjugation process capabilities worth evaluating.
Evidence Ledger: What Is the Quality of Available Data?
| Claim | Best Evidence Type | Direction | Confidence |
|---|---|---|---|
| Bachem, PolyPeptide, Lonza are largest GMP peptide CDMOs by capacity | Company public disclosures, industry analyst reports (CPhI, DCAT) | Consistent across sources | Moderate |
| Fmoc SPPS is the dominant commercial peptide synthesis platform | Peer-reviewed process chemistry literature (multiple authors, Journal of Peptide Science) | Strongly established | High |
| TFA counterion is a formulation and safety concern in injectables | ICH guidance, published pharmacokinetic and tolerability literature | Regulatory consensus | High |
| Process development timelines of 6 to 18 months before first GMP batch | Industry consensus across CDMO technical disclosures; no formal RCT possible | Directionally consistent | Moderate |
| ICH Q6B analytical package adequacy for peptide regulatory submissions | ICH Q6B guidance document (official regulatory guidance) | Authoritative regulatory standard | High |
| Specific cost-per-gram figures for GMP peptide APIs | Not available in published literature; highly project-specific | Not estimable here | Very Low (omitted) |
| PolyPeptide has supported more than 30 approved peptide APIs | Company public disclosure (PolyPeptide Group investor materials) | Company-reported | Low to Moderate (unverified externally) |
How Does SPPS Scale-Up Actually Work, with Real Numbers?
Solid-phase peptide synthesis anchors the C-terminal amino acid to a polystyrene or PEG-based resin bead via a linker. Each subsequent amino acid is added in protected form (Fmoc protecting the alpha-amine) through a deprotection, activation, and coupling cycle. At research scale this runs in reactors of 0.1 mmol to 10 mmol. Commercial GMP synthesis runs in dedicated reactors that can exceed 1,000 liters of resin slurry volume.
Key numbers that matter for CDMO evaluation:
- Coupling efficiency per cycle: Modern automated synthesis achieves greater than 99 percent coupling efficiency per residue under optimized conditions. For a 30-residue peptide, 99 percent per-step efficiency yields roughly 74 percent of theoretical maximum crude peptide before purification. Falling to 98 percent per step drops that to approximately 55 percent for the same sequence, which directly raises cost-of-goods.
- Crude purity before HPLC: For a straightforward linear peptide, crude purity off the synthesizer is typically 60 to 85 percent. Difficult sequences (hydrophobic clusters, aspartimide-prone Asp-Gly motifs, aggregation-prone stretches) can fall well below this range.
- HPLC purification loss: Preparative RP-HPLC typically recovers 50 to 80 percent of the crude peptide mass as specification-grade material, depending on purity target and peak resolution. This yield loss is a major cost driver and is the step where CDMO-specific process chemistry expertise has the largest impact.
- What this does NOT prove: High coupling efficiency in a vendor's technical summary does not guarantee the same result on your specific sequence. Sequence-specific problems (racemization at His or Cys, deletion sequences from difficult couplings, oxidation of Met) require empirical optimization. Ask for sequence-specific feasibility data, not generic platform statistics.
What Most CDMO Comparison Pages Get Wrong
This is the section commodity listicles omit.
They conflate research-grade and GMP capability. A CDMO that can deliver high-purity peptide for research use (greater than 95 percent by RP-HPLC) does not automatically have the regulatory infrastructure for GMP. GMP requires qualified analytical methods, batch record systems, deviation handling, stability protocols, and a quality system that can survive an FDA or EMA inspection. These are organizational capabilities, not just equipment. Ask for the most recent inspection outcome, not a list of equipment.
They ignore the resin and reagent supply chain. The coupling reagents (HATU, HBTU, DIC and the specific resin support) used in SPPS are themselves subject to supply variability and vendor qualification. A CDMO that manufactures its own key reagents in-house (Bachem does this for certain materials) has a supply chain advantage over one that purchases from a single external vendor. This rarely appears in marketing materials but matters for commercial continuity.
They do not address tech transfer risk. Moving a peptide process from development-scale to commercial-scale at the same CDMO is not automatic. Purification gradients that work at 10-gram scale often require substantial re-optimization at kilogram scale due to column dynamics and thermal management in large-bed HPLC. CDMOs with documented scale-up case studies are preferable to those offering only theoretical claims about scalability.
They do not mention impurity profiling requirements. ICH Q3A and Q6B require that process-related impurities (deletion sequences, epimers, oxidation products) be identified and controlled. This requires LC-MS/MS capability, not just RP-HPLC. Many smaller CDMOs do not have in-house tandem MS, meaning impurity identification must be outsourced, slowing regulatory timelines and adding cost.
Why TFA Counterion Matters: The Chemistry Behind the Rule
Trifluoroacetic acid (TFA) is used in Fmoc SPPS for two distinct purposes: Fmoc deprotection uses piperidine (not TFA), but the global deprotection of side-chain protecting groups and cleavage from the resin uses a cocktail that is typically 90 to 95 percent TFA. After cleavage, the free peptide is precipitated in cold diethyl ether, but TFA binds ionically to the basic residues (Lys, Arg, His, N-terminus) as a trifluoroacetate counterion.
The trifluoroacetate anion is biologically active at sufficient concentrations. Published tolerability data in animal models and case reports in human pharmacology literature raise concerns about cardiac and mitochondrial effects at high doses, though injectable clinical peptides are dosed at quantities where the absolute TFA load may be low. The more consistent concern is that regulatory agencies (EMA in particular, via CHMP guidance) have flagged TFA as an impurity requiring characterization and justification in parenteral products.
The practical route to TFA removal is ion-exchange chromatography using an acetate, chloride, or phosphate mobile phase, or repeated lyophilization from dilute acetic acid. Both add process steps and cost. CDMOs that perform this conversion routinely will have the step built into their GMP process; those that do not may deliver a peptide meeting the HPLC purity specification while still carrying a TFA counterion load that is not compatible with your formulation or regulatory strategy.
Operational implication: The COA should specify the counterion by name and include a quantitative value (typically by ion chromatography or NMR). A COA listing only RP-HPLC purity and mass is insufficient for injectable-grade material regardless of the purity number.
Head-to-Head Comparison Table
| CDMO | Max GMP Scale | Complex Peptide Capability | Regulatory Filing Track Record | Analytical In-House MS | Multi-Continent GMP | Best Phase Fit |
|---|---|---|---|---|---|---|
| Bachem | Multi-hundred kg/year | High (cyclic, lipidated, non-natural AA) | Multiple approved drugs, FDA and EMA inspected | Yes | Yes (CH, USA) | Phase I through commercial |
| PolyPeptide Group | Multi-hundred kg/year | High | 30+ approved APIs, multi-agency | Yes | Yes (SE, DK, FR, USA, IN) | Phase I through commercial |
| Lonza Peptide Synthesis | Large commercial | High (lipidated, GLP-1 class) | Strong, integrated with Lonza biologics filings | Yes | Yes (CH, USA) | Phase II through commercial |
| Almac Sciences | Mid-scale (Phase I to III) | Moderate to High (stapled, PDC) | Solid early-phase regulatory support | Yes | Yes (UK, USA) | Phase I through Phase III |
| CPC Scientific | Small to mid-scale | Moderate | Limited public GMP regulatory track record | Partial | Yes (USA, CN) | Research to Phase I |
| CordenPharma | Large commercial | High (conjugates, PEGylation) | Strong (small molecule heritage plus peptide) | Yes | Yes (multiple EU sites) | Phase II through commercial |
| WuXi STA | Large commercial | Moderate to High | Growing, FDA-inspected sites | Yes | Yes (CN, USA) | Phase I through commercial |
Where peptide CDMOs lose vs. alternatives: For very short peptides of 2 to 5 residues, classical small-molecule synthesis or enzymatic routes may outcompete SPPS on cost and yield. For large cyclic peptides above roughly 20 residues, hybrid SPPS-solution-phase or cell-free synthesis platforms at specialized boutique CDMOs may offer advantages that large-volume SPPS CDMOs have not optimized for.
Can a CDMO Handle Cyclic, Stapled, or Lipidated Peptides?
These modifications require distinct chemistry platforms and not all CDMOs claiming GMP peptide capability have invested in all of them.
- Cyclic peptides require either on-resin cyclization (head-to-tail, side-chain-to-side-chain, or disulfide) or solution-phase cyclization after cleavage. The main technical challenge is controlling intramolecular versus intermolecular reaction (concentration management) and confirming the cyclization regiochemistry by MS and NMR. Ask the CDMO for a representative cyclization yield from their process development runs.
- Hydrocarbon-stapled peptides (all-hydrocarbon cross-links via ring-closing olefin metathesis using Grubbs catalyst) require specialized metathesis chemistry and catalyst handling, and GMP-compatible Grubbs catalyst sourcing is a supply chain complexity. Only a subset of CDMOs has established GMP metathesis protocols. Aileron Therapeutics and academic groups pioneered the chemistry; commercial GMP capacity remains limited as of 2025.
- Lipidated peptides (fatty acid conjugated, as in semaglutide class) require selective conjugation chemistry (often via a linker such as mini-PEG attached to a glutamic acid spacer) and specialized purification to separate mono-lipidated from di-lipidated species. Lonza and Bachem have publicly disclosed GLP-1 class analog manufacturing experience, which is the best proxy indicator for this capability.
How to Read a Peptide CDMO's COA and DMF
This is the operational section most buyers skip until a regulatory review flags a problem.
COA minimum data set for injectable-grade GMP peptide:
| Test | Method | Why It Matters |
|---|---|---|
| Identity | ESI-MS or MALDI, observed vs. theoretical mass within instrument accuracy | Confirms correct primary structure |
| Purity | RP-HPLC with column conditions specified, peak area percent | Core quality attribute |
| Chiral purity (epimer content) | Chiral HPLC or amino acid analysis after hydrolysis | Racemization at Cys, His is a known SPPS failure mode |
| Water content | Karl Fischer titration | Affects true mass for dosing calculations |
| Counterion | Ion chromatography or quantitative NMR | TFA vs. acetate distinction is regulatory requirement for injectables |
| Residual solvents | GC headspace, ICH Q3C limits | DMF, NMP, DCM residuals from synthesis |
| Endotoxin | LAL or recombinant Factor C assay | Required for parenteral grade material |
| Peptide content (net) | Amino acid analysis or UV (if chromophore present) | Actual peptide mass corrected for water and counterion |
DMF evaluation: A Type II Drug Master File is a confidential submission to the FDA. You cannot read the full contents, but you can verify the DMF number exists in FDA's DMF database (publicly searchable at FDA.gov), check the date of the most recent annual update (an unmaintained DMF is a red flag), and request that the CDMO provide you a letter of authorization so your IND references their DMF. Verify that the DMF covers the specific synthesis platform and site you are using, not a different facility.
Red Flags and Green Flags When Qualifying a Peptide CDMO
| Signal | Red Flag | Green Flag |
|---|---|---|
| Synthesis location | Sub-contracted; CDMO is a broker | On-site SPPS reactors at stated facility |
| Analytical capability | COA has HPLC purity only, no MS | In-house LC-MS/MS for impurity profiling |
| Regulatory filings | No DMF or ASMF, no inspection history | Active DMF with recent annual update, documented inspection outcome |
| TFA counterion | COA does not specify counterion; assumes acetate without quantification | Counterion quantified by ion chromatography or NMR |
| Scale-up data | Only theoretical scalability claims | Documented tech transfer case study at similar scale |
| Reagent sourcing | Single-source coupling reagents with no backup supplier qualified | Dual-qualified reagent sources or in-house production |
| Pricing transparency | No binding milestone schedule; open-ended cost proposals | Fixed-price milestones with defined deliverables and rework clauses |
FAQ
What makes a CDMO good at peptide therapeutics process development?
The most important indicators are in-house SPPS and solution-phase synthesis capability, GMP-certified purification (typically preparative HPLC), an analytical package matching ICH Q6B, demonstrated scale-up from milligram to kilogram, and a regulatory track record of DMF or ASMF filings. Generic biotech CDMOs without peptide-specific purification hardware are rarely competitive.
Which CDMOs have the largest GMP peptide manufacturing capacity?
PolyPeptide Group, Bachem, and Lonza Peptide Synthesis operate the largest dedicated GMP peptide facilities as of 2025, each with multi-hundred-kilogram annual API capacity. Almac Sciences and CPC Scientific offer mid-tier GMP scale suitable for Phase I through Phase III.
What is SPPS and why does it matter for CDMO selection?
Solid-phase peptide synthesis (SPPS) attaches the growing amino-acid chain to a solid resin support, enabling rapid coupling cycles and automated synthesis. CDMOs that own large-bed synthesizers can deliver GMP batches without outsourcing the core synthesis step, reducing contamination risk and improving chain-of-custody documentation.
How do I evaluate a CDMO's analytical capability for peptides?
Request evidence of RP-HPLC purity determination, mass spectrometry (ESI-MS or MALDI), amino acid analysis, chiral purity testing, residual solvent analysis per ICH Q3C, and counterion quantification. Any GMP CDMO aiming for regulatory submission should offer a certificate of analysis with all these data points per ICH Q6B guidance.
What are the biggest red flags when evaluating a peptide CDMO?
Key red flags include: no GMP-certified purification suite on-site, inability to provide a Drug Master File or reference prior regulatory filings, no in-house analytical MS capability, vague delivery timelines without milestone contracts, and quotations that do not specify resin source or coupling chemistry. Undisclosed sub-contracting of synthesis is a serious quality risk.
Can smaller CDMOs handle complex peptides like cyclic or lipidated peptides?
Yes, but capability varies significantly. Cyclic peptides require on-resin or solution-phase cyclization steps. Lipidated peptides need fatty acid conjugation and specialized purification. Before engaging any CDMO, ask specifically whether they have GMP experience with your modification type and request example COA data or case studies.
What is the typical timeline for GMP peptide process development at a CDMO?
Process development for a novel peptide API typically runs 6 to 18 months before a first GMP batch, depending on sequence complexity, required purity specification, and whether analytical methods need to be developed from scratch. Novel cyclic or conjugated peptides sit at the longer end of that range.
How should I read a peptide CDMO's certificate of analysis?
Check that the COA lists: identity confirmation by MS, RP-HPLC purity with column and gradient conditions specified, water content by Karl Fischer, counterion identity and quantification, residual solvents, and endotoxin if injectable grade. A COA reporting only HPLC purity without MS is insufficient for regulatory purposes.
Is it better to use a single CDMO for both development and commercial manufacturing?
A single-CDMO path reduces tech-transfer risk and keeps institutional process knowledge in one place. Dual-sourcing reduces supply risk and can create competitive pricing pressure at commercial scale. Most regulatory agencies do not require dual-sourcing, but sponsors in late Phase III often establish a second site for business continuity.
What regulatory filings should a peptide CDMO be able to support?
At minimum: a US Type II Drug Master File or EU Active Substance Master File, GMP compliance with FDA 21 CFR Part 211 or EU GMP Annex 1 and Annex 11, ICH Q7 (API GMP), and the ability to supply analytical data packages for IND, CTA, NDA, or MAA submissions. Ask whether they have been subject to FDA or EMA inspections and the outcome.
How does cost scale with peptide length and purity specification at a CDMO?
Cost increases with each additional amino acid residue (more coupling cycles, lower crude yield) and rises steeply with purity targets above roughly 98 percent. GMP batches for clinical use carry a regulatory compliance cost on top of synthesis cost. Difficult sequences with aggregation-prone stretches require additional optimization cycles that add to project cost.
What is TFA removal and why does it matter for injectable peptide APIs?
Trifluoroacetic acid (TFA) is the standard cleavage reagent in Fmoc SPPS and remains as a counterion on purified peptide unless explicitly exchanged by ion-exchange chromatography or lyophilization from dilute acid. Regulatory agencies flag TFA as an impurity requiring characterization in parenteral products. Injectable-grade peptides should be supplied as acetate or chloride salts with quantified counterion content on the COA.
Sources
- ICH Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. International Council for Harmonisation, 1999. Available at ich.org.
- ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. International Council for Harmonisation, 2000. Available at ich.org.
- ICH Q3C: Impurities: Guideline for Residual Solvents. International Council for Harmonisation, revised 2011. Available at ich.org.
- Behrendt R, White P, Offer J. Advances in Fmoc solid-phase peptide synthesis. Journal of Peptide Science. 2016;22(1):4-27. PMID 26785684.
- Isidro-Llobet A, et al. Sustainability challenges in peptide synthesis and purification: from research to commercial manufacturing. Journal of Organic Chemistry. 2019;84(8):4615-4628. PMID 30908910.
- Palasek SA, Cox ZJ, Collins JM. Limiting racemization and aspartimide formation in microwave-enhanced Fmoc solid phase peptide synthesis. Journal of Peptide Science. 2007;13(3):143-
Related peptide guides